Wall Street analysts expect Cronos Group Inc (NASDAQ:CRON) to report earnings per share (EPS) of ($0.03) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Cronos Group’s earnings, with the lowest EPS estimate coming in at ($0.06) and the highest estimate coming in at $0.00. Cronos Group also posted earnings per share of ($0.03) in the same quarter last year. The company is scheduled to report its next quarterly earnings results on Tuesday, November 12th.
According to Zacks, analysts expect that Cronos Group will report full year earnings of ($0.07) per share for the current year, with EPS estimates ranging from ($0.10) to ($0.05). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.09) per share, with EPS estimates ranging from ($0.32) to $0.07. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Cronos Group.
Cronos Group (NASDAQ:CRON) last posted its earnings results on Thursday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Cronos Group had a return on equity of 60.20% and a net margin of 2,521.25%. The firm had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $7.16 million. Cronos Group’s revenue for the quarter was up 217.6% compared to the same quarter last year.
CRON opened at $11.40 on Tuesday. Cronos Group has a 52-week low of $6.50 and a 52-week high of $25.10. The stock has a market capitalization of $3.89 billion, a PE ratio of 42.89 and a beta of 3.43. The stock’s 50 day moving average price is $13.99 and its 200-day moving average price is $16.90.
A number of hedge funds have recently modified their holdings of CRON. ETF Managers Group LLC purchased a new stake in Cronos Group in the second quarter worth $95,437,000. Vanguard Group Inc. grew its stake in Cronos Group by 77.7% in the second quarter. Vanguard Group Inc. now owns 9,068,103 shares of the company’s stock worth $144,910,000 after purchasing an additional 3,966,024 shares during the period. Janus Henderson Group PLC grew its stake in Cronos Group by 4,474.9% in the second quarter. Janus Henderson Group PLC now owns 800,600 shares of the company’s stock worth $12,871,000 after purchasing an additional 783,100 shares during the period. D. E. Shaw & Co. Inc. grew its stake in Cronos Group by 198.7% in the second quarter. D. E. Shaw & Co. Inc. now owns 335,400 shares of the company’s stock worth $5,360,000 after purchasing an additional 675,200 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Cronos Group in the first quarter worth $12,113,000. 8.16% of the stock is currently owned by institutional investors.
About Cronos Group
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations ?MMPR?. The firm typically invests in companies based in Canada.
Recommended Story: What is the definition of a trade war?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.